Schedule 13G ownership disclosure
BIONDVAX PHARMACEUTICALS LTD
ADSs · CUSIP: 09073Q105
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SABBY MANAGEMENT, LLC
Shares: 29,051.00 · Class: 4.9%
- SABBY VOLATILITY WARRANT MASTER FUND LTD
Shares: 29,051.00 · Class: 4.9%
- HAL MINTZ
Shares: 29,051.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001535610-25-000022
- Form type
- SCHEDULE 13G
- Filer
- SABBY MANAGEMENT, LLC
- CIK
- CIK 1535610
- Filed
- Jan 03, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership